ANS-6637

DRUG3 trials

Sponsors

National Institutes of Health Clinical Center (CC), National Institute on Alcohol Abuse and Alcoholism (NIAAA), University of Maryland, Baltimore

Conditions

Alcohol Use DisorderOpiod Use DisorderOpioid-use Disorder

Phase 1

The Influence of ANS-6637 on Midazolam Pharmacokinetics in Healthy Volunteers

CompletedNCT03831971

National Institutes of Health Clinical Center (CC)Opiod Use Disorder

Start: 2019-03-01End: 2019-12-30Updated: 2020-08-03

Phase 2

HLAB-002 of ANS-6637 for Alcohol Use Disorder

TerminatedNCT03970109

National Institute on Alcohol Abuse and Alcoholism (NIAAA)Alcohol Use Disorder

Start: 2019-10-08End: 2020-05-22Updated: 2024-10-29

Safety and Preliminary Efficacy of ANS-6637 to Reduce Drug Craving and Harm in People With Opioid Use Disorder

WithdrawnNCT04169360

University of Maryland, BaltimoreOpioid-use Disorder

Start: 2021-01-31End: 2021-01-12Updated: 2021-01-28